DOMS Industries Limited — Investor Meet, 08-02-2025: Analysts/Institutional Investor Meet/Con. Call Updates

1. **Financial Performance**: DOMS Industries reported consolidated operating revenues of ₹501.1 crore for Q3 FY25, reflecting a robust 35% year-over-year growth. Without the impact of Uniclan Healthcare, the revenue growth was 21.4%. The consolidated EBITDA rose to ₹87.9 crore, up 26.7% from ₹69.3 crore a year earlier, but margins slightly declined to 17.5% due to increased sales costs from Uniclan and ESOP accounting. The consolidated profit after tax surged by nearly 40%, reaching ₹54.3 crore compared to ₹38.8 crore in Q3 FY24.

2. **Future Outlook and Growth Drivers**: Management remains cautiously optimistic about future demand, projecting a full revenue growth of 23% to 25% for FY25, supported by upcoming back-to-school trends and government spending on education. There are ambitious plans for product launches and distribution network expansion, indicating a strong pipeline for growth.

3. **Order Book and Operational Updates**: The operational initiatives include a third diaper production line at Uniclan, enhancing capacity. Additionally, a 1 MW solar plant has been installed at the Umargam facility to bolster sustainability efforts.

4. **Analyst Q&A Insights (Detailed)**:

- **Revenue and Profitability**: Queries about export sales and profitability were addressed, noting a 5% decline in exports due to geopolitical issues but anticipated recovery.

- **Market Position and Competitive Landscape**: Concerns about competition and market share were met with confidence, citing ongoing distribution agreements and robust demand in domestic markets.

- **Operational Challenges or Risks**: Management acknowledged current challenges but affirmed strong strategies to mitigate risks and continue growth.

- **Capex and Capital Allocation**: Future capex is expected between ₹200 to ₹225 crore, aimed at enhancing operational capacity.

- **Strategic Priorities and Long-Term Vision**: Innovations and sustainability initiatives remain a focus, with plans for capacity enhancements in the stationery and hygiene segments.

5. **Market or Regulatory Updates**: No significant regulatory updates were detailed, but the focus remains on navigating current market dynamics and expected recovery in export markets.

6. **Strategic Focus Areas**: Emphasis on innovation, sustainability, and strategic partnerships, particularly in exports, reflects management's confidence and a forward-looking approach.

7. **Investor Insight**: The financial health and growth trajectory suggest a favorable outlook potentially aligning with a 'buy' stance, driven by solid revenue growth, strategic expansions, and an optimistic demand recovery narrative. However, investor caution is warranted given existing geopolitical risks and market conditions.